Evidence map›Paper›PMID 27595322›Full record

ArticleNature medicine2016

Serotonin-reuptake inhibitors act centrally to cause bone loss in mice by counteracting a local anti-resorptive effect.

María José Ortuño, Samuel T Robinson, Prakash Subramanyam, Riccardo Paone, Yung-Yu Huang, X Edward Guo, Henry M Colecraft, J John Mann, Patricia Ducy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2018
    Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Bone Turnover with Venlafaxine Treatment in Older Adults with Depression.Journal of the American Geriatrics Society · 2017
    Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Bone-organ axes: bidirectional crosstalk.Military Medical Research · 2024
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

María José OrtuñoDepartment of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Samuel T RobinsonDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.
Prakash SubramanyamDepartment of Physiology and Cellular Biophysics, Columbia University, New York, New York, USA.
Riccardo PaoneDepartment of Genetics and Development, College of Physicians and Surgeons, Columbia University, New York, New York, USA.ORCID 0000-0002-8688-9191
Yung-Yu HuangDepartment of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
X Edward GuoDepartment of Biomedical Engineering, Columbia University, New York, New York, USA.
Henry M ColecraftDepartment of Physiology and Cellular Biophysics, Columbia University, New York, New York, USA.
J John MannDepartment of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Patricia DucyDepartment of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, New York, USA.
Columbia University · USUniversity of L'Aquila · IT

Funding

Transcriptomic CoreP01AG032959 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gerard Karsenty · 2010 to 2026
$39.7M
NIA NIH HHS P01 AG032959
6 · The paper itself

Abstract

The use of selective serotonin-reuptake inhibitors (SSRIs) has been associated with an increased risk of bone fracture, raising concerns about their increasingly broader usage. This deleterious effect is poorly understood, and thus strategies to avoid this side effect remain elusive. We show here that fluoxetine (Flx), one of the most-prescribed SSRIs, acts on bone remodeling through two distinct mechanisms. Peripherally, Flx has anti-resorptive properties, directly impairing osteoclast differentiation and function through a serotonin-reuptake-independent mechanism that is dependent on intracellular Ca

Indexed as

Adrenergic beta-AntagonistsAnimalsBone and BonesBone RemodelingBone ResorptionCalciumFluoxetineGene ExpressionImmunohistochemistryIn Vitro TechniquesMiceMice, KnockoutNFATC Transcription FactorsOptical ImagingOsteogenesisPropranololAdrenergic beta-AntagonistsCalciumFluoxetineNfatc1 protein, mouseNFATC Transcription FactorsPropranololSelective Serotonin Reuptake InhibitorsSerotonin Plasma Membrane Transport ProteinsSlc6a4 protein, mouseTph1 protein, mouseTryptophan Hydroxylase

Identifiers

PMID27595322
PMCPMC5053870
OpenAlexW2508806705

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.